Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Robert Cascella is Director at Koru Medical Systems. OQRO lists 8 transactions filed with the SEC under this name, the latest on Oct 1, 2026, each linked to the official Form 4.
Director
Disclosures on record
8
Companies involved
3
As of the latest filing on , Robert Cascella reported holding 625,017 shares of Neuronetics (STIM), worth about $869K at the last close of $1 (Nov 13, 2026). Holdings are also on file at Koru Medical Systems (KRMD), Celestica (CLS); together they are worth about $1.32M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Neuronetics STIM | 625,017 | 625K direct | $1 | $869K | May 28, 2026 |
| Koru Medical Systems KRMD | 103,274 | 103K direct | $4 | $382K | Oct 1, 2026 |
| Celestica CLS | 272 | 272 direct | $240 | $65K | Sep 30, 2026 |
Is this Robert Cascella’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Koru Medical SystemsKRMD
4 disclosures · Jan 2026 – Oct 2026
Oct 1, 20265,119
DetailsOfficial recordJul 1, 20263,571
DetailsOfficial recordApr 1, 20263,472
DetailsOfficial recordJan 2, 20262,581
DetailsOfficial recordCelesticaCLS
3 disclosures · Oct 2026
Sep 30, 202652disclosed Oct 1
DetailsOfficial recordSep 30, 202652disclosed Oct 1
DetailsOfficial recordSep 30, 20266disclosed Oct 1
DetailsOfficial recordNeuroneticsSTIM
May 28, 202636Kdisclosed May 29
DetailsOfficial recordRobert Cascella bought shares on the open market in 2021, 2023 and 2024, and has not bought since 2024 across 2 companies.
Robert Cascella reported 10 open-market purchases and 0 sales since 2021; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $278K6×6 trades | — |
| 2023 | $101K2×2 trades | — |
| 2021 | $162K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 28, 2026, Robert Cascella reported holding 625,017 shares of Neuronetics (STIM). At the last close of $1 on Nov 13, 2026, that is about $869K. This is the stake disclosed in filings, not a net worth.
Robert Cascella bought shares on the open market in 2021, 2023 and 2024, and has not bought since 2024 across 2 companies.
In SEC filings since 2021: the latest open-market purchase is from 2024; no open-market sale is on record.
2 companies: Neuronetics (STIM, 2021–2024), Koru Medical Systems (KRMD, 2023).
Robert Cascella reported 9 open-market purchases and 0 sales here, 2021 to 2024.
Robert Cascella reported 1 open-market purchase and 0 sales here, 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
